Extravasation with Trabectedin(Yondelis: ET-743) Troubles with the Use of Cytostatic Agents
Extravasation with Trabectedin (Yondelis: ET-743) Troubles with the Use of Cytostatic Agents
The use of chemotherapeutic agents can be the cause of local or systemic toxicity. Extravasation is a serious phenomenon which can lead to chronic and irreversible side- effects. In 2007, trabectedin (Yondelis®; ET- 743) obtained a commercial license of the European Medicines Agency (EMA) for the treatment of adult patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide or who are unsuited to receive these agents. Since 2009, trabectedin in combination with pegylated liposomal doxorubicin (PLD) is also indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. We report a case of an ovarian cancer patient with a cytotoxic reaction due to an extravasation of trabectedin. This situation has been rarely reported in the literature. To our knowledge, there is only one reference with two cases of an identical type of extravasation with the same product.